Companies Dominating the Hyaluronidase Landscape
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- PrimaPharm Inc.
- Valeant Pharmaceuticals
- Halozyme Therapeutics
- CooperSurgical Fertility Companies
- Amphastar Pharmaceuticals Inc.
- Shreya Life Science
- Bausch & Lomb Incorporated
- Stemcell Technologies Inc.
- Anika Therapeutics Inc.
- Alteogen Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Alteogen Inc., a South Korean biotechnology company, announced that the recently completed Tergase clinical trial showed no cases of ADA, including neutralizing antibodies. Tergase is Alteogen's first proprietary product currently undergoing the pharmaceutical approval process by the Korean Ministry of Food and Drug Safety. Tergase is a stand-alone hyaluronidase product that can be used to treat various medical conditions, such as pain relief, edema treatment, and hyaluronic acid filler removal. In particular, compared to animal-derived hyaluronidase products available on the market, this is a high quality, highly pure product with very few impurities and has excellent few side effects. As a new recombinant human hyaluronidase, Alteogen hopes Tergase can be applied to new indications not currently available for existing animal-derived products.
- Halozyme Therapeutics, Inc. announced in June 2023 that argenx received approval from the U.S. Food and Drug Administration (FDA) for VYVGART Hytrulo Injection with ENHANZE for subcutaneous use in the treatment of generalized myasthenia gravis in Adult patients positive for anti-acetylcholine receptor antibodies.
